Show simple item record

dc.contributor.authorLambert, Laura A.
dc.date2022-08-11T08:10:58.000
dc.date.accessioned2022-08-23T17:26:50Z
dc.date.available2022-08-23T17:26:50Z
dc.date.issued2015-07-01
dc.date.submitted2016-05-11
dc.identifier.citationCA Cancer J Clin. 2015 Jul-Aug;65(4):284-98. doi: 10.3322/caac.21277. Epub 2015 May 4. <a href="http://dx.doi.org/10.3322/caac.21277">Link to article on publisher's website</a>
dc.identifier.issn1542-4863
dc.identifier.doi10.3322/caac.21277
dc.identifier.pmid25940594
dc.identifier.urihttp://hdl.handle.net/20.500.14038/49727
dc.description.abstractUntil recently, a diagnosis of peritoneal carcinomatosis was uniformly accompanied by a grim prognosis that was typically measured in weeks to months. Consequently, the management of carcinomatosis revolves largely around palliation of symptoms such as bowel obstruction, nausea, pain, fatigue, and cachexia. A prior lack of effective treatment options created the nihilistic view that currently exists and persists despite improvements in the efficacy of systemic therapy and the evolution of multimodality approaches including surgery and intraperitoneal chemotherapy. This article reviews the evolution and current state of treatment options for patients with peritoneal carcinomatosis. In addition, it highlights recent advances in understanding the molecular biology of carcinomatosis and the focus of current and future clinical trials. Finally, this article provides practical management options for the palliation of common complications of carcinomatosis. It is hoped that the reader will recognize that carcinomatosis is no longer an imminent death sentence and that through continued research and therapeutic innovation, clinicians can make an even greater impact on this form of metastatic cancer.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&list_uids=25940594&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.3322/caac.21277
dc.subjectAntineoplastic Agents
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCarcinoma
dc.subjectCombined Modality Therapy
dc.subjectCytoreduction Surgical Procedures
dc.subjectHumans
dc.subjectHyperthermia, Induced
dc.subjectInfusions, Parenteral
dc.subjectPalliative Care
dc.subjectPeritoneal Neoplasms
dc.subjectTreatment Outcome
dc.subjectperitoneal
dc.subjectcarcinomatosis
dc.subjecthyperthermic intrape ritoneal chemoperfusion (HIPEC)
dc.subjectcytoreduction
dc.subjectascites
dc.subjecthyper-thermic
dc.subjectchemoperfusion
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectSurgery
dc.titleLooking up: Recent advances in understanding and treating peritoneal carcinomatosis
dc.typeJournal Article
dc.source.journaltitleCA: a cancer journal for clinicians
dc.source.volume65
dc.source.issue4
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/surgery_pp/152
dc.identifier.contextkey8592164
html.description.abstract<p>Until recently, a diagnosis of peritoneal carcinomatosis was uniformly accompanied by a grim prognosis that was typically measured in weeks to months. Consequently, the management of carcinomatosis revolves largely around palliation of symptoms such as bowel obstruction, nausea, pain, fatigue, and cachexia. A prior lack of effective treatment options created the nihilistic view that currently exists and persists despite improvements in the efficacy of systemic therapy and the evolution of multimodality approaches including surgery and intraperitoneal chemotherapy. This article reviews the evolution and current state of treatment options for patients with peritoneal carcinomatosis. In addition, it highlights recent advances in understanding the molecular biology of carcinomatosis and the focus of current and future clinical trials. Finally, this article provides practical management options for the palliation of common complications of carcinomatosis. It is hoped that the reader will recognize that carcinomatosis is no longer an imminent death sentence and that through continued research and therapeutic innovation, clinicians can make an even greater impact on this form of metastatic cancer.</p>
dc.identifier.submissionpathsurgery_pp/152
dc.contributor.departmentDepartment of Surgery
dc.source.pages284-98


This item appears in the following Collection(s)

Show simple item record